MindImmune Therapeutics

United States
Cairnbrook, Pennsylvania, United States

Company profile

MindImmune Therapeutics company profile

MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated. Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.

Business identity

Contact email
[email protected]
Phone number
401-225-4612
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
4
Total equity funding
$23.9M
Last funding
Series A / $10.2M / 2025-11-24
Last equity funding
Series A / $10.2M
Investors
8
Lead investors
2
Founders
3
Articles
14

Founders and investors

Founders

Brian M CampbellFrank S. MennitiStevin Zorn

Lead investors

Dolby Family VenturesSlater Technology Fund

Investors

Alzheimer's Drug Discovery FoundationDolby Family VenturesGates Frontier FundPfizer Venture InvestmentsSlater Technology Fund